News
-
-
-
COMMUNIQUÉ DE PRESSE
Bausch Health, Canada Inc. Announces Additional Public Drug Plan Listings for PrUCERIS(R) (Budesonide) Aerosol Foam To Treat Mild to Moderate Distal Ulcerative Colitis in Adults
Bausch Health Canada expands UCERIS availability in Canadian public drug plans for ulcerative colitis treatment. UCERIS foam offers better tolerability and application compared to enema -
-
-
COMMUNIQUÉ DE PRESSE
Salix to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024
Bausch Health & Salix Pharmaceuticals to present Phase 2 trial data on Amiselimod for ulcerative colitis treatment at DDW 2024. Positive results announced in 2023 -
-
-
-